204 related articles for article (PubMed ID: 34250834)
41. Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis.
Varshney AS; Wang DE; Bhatt AS; Blood A; Sharkawi MA; Siddiqi HK; Vaduganathan M; Monteleone PP; Patel MR; Jones WS; Lopes RD; Mehra MR; Bhatt DL; Kochar A
Am Heart J; 2021 Feb; 232():105-115. PubMed ID: 33121978
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis.
Hariyanto TI; Hardyson W; Kurniawan A
Drug Res (Stuttg); 2021 May; 71(5):265-274. PubMed ID: 33401328
[TBL] [Abstract][Full Text] [Related]
43. Role of Colchicine in Stroke Prevention: An Updated Meta-Analysis.
Masson W; Lobo M; Molinero G; Masson G; Lavalle-Cobo A
J Stroke Cerebrovasc Dis; 2020 May; 29(5):104756. PubMed ID: 32160956
[TBL] [Abstract][Full Text] [Related]
44. Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19.
Tardif JC; Cossette M; Guertin MC; Bouabdallaoui N; Dubé MP; Boivin G;
Int J Infect Dis; 2022 Mar; 116():387-390. PubMed ID: 35038601
[TBL] [Abstract][Full Text] [Related]
45. Psychopharmacology of COVID-19.
Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
[TBL] [Abstract][Full Text] [Related]
46. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
47. Colchicine in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Trials.
Kofler T; Kurmann R; Lehnick D; Cioffi GM; Chandran S; Attinger-Toller A; Toggweiler S; Kobza R; Moccetti F; Cuculi F; Jolly SS; Bossard M
J Am Heart Assoc; 2021 Aug; 10(16):e021198. PubMed ID: 34369166
[TBL] [Abstract][Full Text] [Related]
48. Colchicine administration for percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
Fu C; Wang B
Am J Emerg Med; 2021 Aug; 46():121-125. PubMed ID: 33744748
[TBL] [Abstract][Full Text] [Related]
49. Colchicin treatment of COVID-19 presenting with cutaneous rash and myopericarditis.
Recalcati S; Piconi S; Franzetti M; Barbagallo T; Prestinari F; Fantini F
Dermatol Ther; 2020 Nov; 33(6):e13891. PubMed ID: 32584431
[No Abstract] [Full Text] [Related]
50. COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review.
Nas K; Eryilmaz N; Geyik MF; Altaş A
Rheumatol Int; 2021 Apr; 41(4):811-817. PubMed ID: 33611657
[TBL] [Abstract][Full Text] [Related]
51. Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.
Demidowich AP; Levine JA; Apps R; Cheung FK; Chen J; Fantoni G; ; Patel TP; Yanovski JA
Int J Obes (Lond); 2020 Aug; 44(8):1793-1799. PubMed ID: 32461554
[TBL] [Abstract][Full Text] [Related]
52. Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins.
Abdeen S; Abu-Fanne R; Bdeir K; Maraga E; Higazi M; Cines DB; Heyman SN; Higazi AA
Br J Haematol; 2022 Feb; 196(4):923-927. PubMed ID: 34622440
[TBL] [Abstract][Full Text] [Related]
53. Colchicine in the management of Covid-19: With or lieu of evidence.
Al-Kuraishy HM; Hussien NR; Al-Niemi MS; Al-Gareeb AI
J Pak Med Assoc; 2021 Dec; 71(Suppl 8)(12):S127-S132. PubMed ID: 35130235
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: A randomized, controlled clinical trial.
Silveira MAD; De Jong D; Berretta AA; Galvão EBDS; Ribeiro JC; Cerqueira-Silva T; Amorim TC; Conceição LFMRD; Gomes MMD; Teixeira MB; Souza SP; Santos MHCAD; San Martin RLA; Silva MO; Lírio M; Moreno L; Sampaio JCM; Mendonça R; Ultchak SS; Amorim FS; Ramos JGR; Batista PBP; Guarda SNFD; Mendes AVA; Passos RDH;
Biomed Pharmacother; 2021 Jun; 138():111526. PubMed ID: 34311528
[TBL] [Abstract][Full Text] [Related]
55. Potential Role of Colchicine in Combating COVID-19 Cytokine Storm and Its Ability to Inhibit Protease Enzyme of SARS-CoV-2 as Conferred by Molecular Docking Analysis.
Kamel NA; Ismail NSM; Yahia IS; Aboshanab KM
Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056328
[TBL] [Abstract][Full Text] [Related]
56. FRAGILE-COLCOVID19: A Clinical Trial Based on Early Administration of an Oral Combination of Colchicine and Prednisone in Elderly Patients with COVID-19 in Geriatric Facilities.
Hernández-Rodríguez J; Durán-Sanclemente J; Prieto-González S; Araújo O; Hospital-Vidal T; Casanovas G; Sapena V; Blanco JL; López-Soto A;
Clin Drug Investig; 2022 Nov; 42(11):949-964. PubMed ID: 36173596
[TBL] [Abstract][Full Text] [Related]
57. COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response.
Akodad M; Lattuca B; Nagot N; Georgescu V; Buisson M; Cristol JP; Leclercq F; Macia JC; Gervasoni R; Cung TT; Cade S; Cransac F; Labour J; Dupuy AM; Roubille F
Arch Cardiovasc Dis; 2017; 110(6-7):395-402. PubMed ID: 28065445
[TBL] [Abstract][Full Text] [Related]
58. Remdesivir for the treatment of COVID-19.
Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
[TBL] [Abstract][Full Text] [Related]
59. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
Kurt T; Aydın F; Nilüfer Tekgöz P; Sezer M; Uncu N; Çelikel Acar B
Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
[TBL] [Abstract][Full Text] [Related]
60. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
